Search

Your search keyword '"Julio Ticona"' showing total 2 results
Start Over Author "Julio Ticona" Topic covid-19
2 results on '"Julio Ticona"'

1. Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Author

Andres Agurto-Arteaga, Astrid Poma-Acevedo, Dora Rios-Matos, Ricardo Choque-Guevara, Ricardo Montesinos-Millán, Ángela Montalván, Gisela Isasi-Rivas, Yudith Cauna-Orocollo, María de Grecia Cauti-Mendoza, Norma Pérez-Martínez, Kristel Gutierrez-Manchay, Ingrid Ramirez-Ortiz, Dennis Núñez-Fernández, Mario I. Salguedo-Bohorquez, Stefany Quiñones-Garcia, Manolo Fernández Díaz, Luis A. Guevara Sarmiento, Mirko Zimic, COVID-19 Working Group in Perú, Ricardo Antiparra, Manuel Ardiles-Reyes, Katherine Calderón, Maria de Grecia Cauti-Mendoza, Naer Chipana-Flores, Xiomara Chunga-Girón, Manuel Criollo-Orozco, Lewis De La Cruz, Nicolás E. Delgado-Pease, Elmer Delgado-Ccancce, Christian Elugo-Guevara, Manolo Fernández-Díaz, Manolo Fernández-Sánchez, Luis Guevara-Sarmiento, Kristel Gutiérrez, Oscar Heredia-Almeyda, Edison Huaccachi-Gonzalez, Pedro Huerta-Roque, Eliana Icochea, Gabriel Jiménez-Avalos, Romina A. Juscamaita-Bartra, Abraham Licla-Inca, Angela Montalván, Adiana Ochoa-Ortiz, Gustavo E. Olivos-Ramirez, Erika Páucar-Montoro, Kathy Pauyac, Jose L. Perez-Martinez, Norma Pérez-M, Daniel Ramos-Sono, Angela A. Rios-Angulo, Aldo Rojas-Neyra, Yomara K. Romero, Yacory Sernaque-Aguilar, Patricia Sheen-Cortavarrı́a, Luis F. Soto, Luis Tataje-Lavanda, Julio Ticona, Katherine Vallejos-Sánchez, A. Paula Vargas-Ruiz, Doris Villanueva-Pérez, Freddy Ygnacio-Aguirre, and Mirko Zimic-Peralta

Subjects
SARS-CoV-2, COVID-19, egg-yolk antibodies, IgY, passive immunization, receptor binding domain, Immunologic diseases. Allergy, RC581-607
Abstract

Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a suitable approach to preclude potential death of infected patients, based on its high specificity/avidity/production yield, cost-effective manufacture, and ease of administration. In the present study, IgY antibodies against a recombinant RBD protein of SARS-CoV-2 were produced in specific-pathogen-free chickens and purified from eggs using a biocompatible method. In vitro immunoreactivity was tested, finding high recognition and neutralization values. Safety was also demonstrated prior to efficacy evaluation, in which body weight, kinematics, and histopathological assessments of hamsters challenged with SARS-CoV-2 were performed, showing a protective effect administering IgY intranasally both as a prophylactic treatment or a post-infection treatment. The results of this study showed that intranasally delivered IgY has the potential to both aid in prevention and in overcoming COVID-19 infection, which should be very useful to control the advance of the current pandemic and the associated mortality.

Published
2022
Full Text
View/download PDF

2. Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease

Author

Manolo Fernández, Díaz, Katherine, Calderón, Aldo, Rojas-Neyra, Vikram N, Vakharia, Ricardo, Choque-Guevara, Angela, Montalvan-Avalos, Astrid, Poma-Acevedo, Dora, Rios-Matos, Andres, Agurto-Arteaga, Maria de Grecia, Cauti-Mendoza, Norma, Perez-Martinez, Gisela, Isasi-Rivas, Luis, Tataje-Lavanda, Yacory, Sernaque-Aguilar, Freddy, Ygnacio, Manuel, Criollo-Orozco, Edison, Huaccachi-Gonzalez, Elmer, Delgado-Ccancce, Doris, Villanueva-Pérez, Ricardo, Montesinos-Millán, Kristel, Gutiérrez-Manchay, Katherinne, Pauyac-Antezana, Ingrid, Ramirez-Ortiz, Stefany, Quiñones-Garcia, Yudith, Cauna-Orocollo, Katherine, Vallejos-Sánchez, Angela, Rios-Angulo, Dennis, Núñez-Fernández, Mario I, Salguedo-Bohorquez, Julio, Ticona, Manolo, Fernández-Sánchez, Eliana, Icochea, Luis A, Guevara-Sarmiento, and Mirko, Zimic

Subjects
Mice, Vaccines, Synthetic, SARS-CoV-2, Cricetinae, Vaccination, Newcastle disease virus, Animals, COVID-19, Viral Vaccines, Antibodies, Viral, Antibodies, Neutralizing, Administration, Intranasal
Abstract

The coronavirus disease-19 (COVID-19) pandemic has already claimed millions of lives and remains one of the major catastrophes in the recorded history. While mitigation and control strategies provide short term solutions, vaccines play critical roles in long term control of the disease. Recent emergence of potentially vaccine-resistant and novel variants necessitated testing and deployment of novel technologies that are safe, effective, stable, easy to administer, and inexpensive to produce. Here we developed three recombinant Newcastle disease virus (rNDV) vectored vaccines and assessed their immunogenicity, safety, and protective efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters. Intranasal administration of rNDV-based vaccine candidates elicited high levels of neutralizing antibodies. Importantly, the nasally administrated vaccine prevented lung damage, and significantly reduced viral load in the respiratory tract of vaccinated animal which was compounded by profound humoral immune responses. Taken together, the presented NDV-based vaccine candidates fully protected animals against SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial as a promising tool in the fight against COVID-19.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results